^
    16h
    Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis (clinicaltrials.gov)
    P2, N=102, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    capecitabine • cyclophosphamide • AiRuiLi (adebrelimab) • Navelbine oral (vinorelbine tartrate oral)
    17h
    CSET 2025 / 4242: First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of systemic chemotherapy (ADJUPANET) (2025-523593-16-00)
    P2/3, N=504, Not yet recruiting, Institut Gustave Roussy
    New P2/3 trial
    |
    temozolomide • capecitabine
    19h
    Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study (clinicaltrials.gov)
    P2, N=130, Completed, The First Affiliated Hospital with Nanjing Medical University | Recruiting --> Completed | Trial completion date: Jul 2027 --> Jun 2026 | Trial primary completion date: Dec 2025 --> May 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    1d
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=96, Recruiting, Tang-Du Hospital | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    capecitabine • oxaliplatin • Hetronifly (serplulimab)
    2d
    Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma (clinicaltrials.gov)
    P2, N=92, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    capecitabine • Teysuno (gimeracil/oteracil/tegafur)
    2d
    Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery (clinicaltrials.gov)
    P3, N=288, Recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P3 trial
    |
    capecitabine
    3d
    A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) (clinicaltrials.gov)
    P2, N=60, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • Onivyde (nanoliposomal irinotecan)
    3d
    Prostate brachytherapy followed by secondary urethral adenocarcinoma: A case report. (PubMed, Urol Case Rep)
    After neoadjuvant oxaliplatin/capecitabine (CAPOX) therapy, he underwent cystoprostatectomy, urethrectomy, and ileal conduit. Pathology showed stage IIIB disease with negative margins. This case underscores a rare but severe complication of prostate brachytherapy, contributing to the clinical understanding of secondary urethral malignancies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification
    |
    capecitabine • oxaliplatin
    5d
    STARTER: Sac-TMT Sequential Capecitabine Versus Capecitabine in Early-Stage High-Risk Triple-Negative Breast Cancer Without BRCA Mutations (clinicaltrials.gov)
    P3, N=420, Not yet recruiting, Fudan University
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • ER negative
    |
    capecitabine • Jiataile (sacituzumab tirumotecan)
    6d
    Management of locally advanced lynch syndrome rectal cancer during pregnancy with neoadjuvant immunochemotherapy: a case report. (PubMed, Front Oncol)
    The patient subsequently underwent neoadjuvant chemoradiotherapy (50.4 Gy in 28 fractions) combined with two cycles of capecitabine plus oxaliplatin (CapeOx) and tislelizumab, achieving significant tumor regression (yT2N0M0). LS-associated rectal cancer during pregnancy requires individualized, multidisciplinary management. Medical termination followed by neoadjuvant immunochemoradiotherapy can optimize maternal outcomes while minimizing fetal and genetic risks.
    Journal
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • PMS2 (PMS1 protein homolog 2)
    |
    Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin
    6d
    To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer (clinicaltrials.gov)
    P2/3, N=574, Recruiting, SUNHO（China）BioPharmaceutical CO., Ltd. | N=90 --> 574 | Trial completion date: Jul 2028 --> Jul 2029 | Trial primary completion date: Jul 2026 --> Jul 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    PD-L1 expression • HER-2 positive • HER-2 expression • HER-2 underexpression • KRAS wild-type • RAS wild-type • NRAS wild-type • HER-2 positive + RAS wild-type
    |
    Herceptin (trastuzumab) • capecitabine • oxaliplatin • IAH0968
    7d
    CapTemY90 for Grade 2/3 NET Liver Metastases (clinicaltrials.gov)
    P2, N=70, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: May 2026 --> Jul 2028 | Trial primary completion date: May 2026 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    temozolomide • capecitabine